Navigation Links
Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients

ctions, and is found in the blood only when there is virus present.

The primary endpoint for the study was mean reduction in HBV DNA levels at week 12. Viral load reduction was also measured at weeks 24 and 48 of the follow-up. Patients received 0.5 mg of BARACLUDE(R) (entecavir) once daily (n=33) or 10 mg of adefovir once daily (n=32).

Patients in the BARACLUDE treatment group had a mean baseline viral load of 10.26 log(10) copies/mL. Patients in the adefovir treatment group had a mean baseline viral load of 9.88 log(10) copies/mL. Data Results

Week 48

* BARACLUDE-treated patients achieved a mean change in viral load of -7.28
log(10) copies/mL, and adefovir-treated patients achieved a mean change
of -5.08 log(10) copies/mL (95 percent Confidence Interval -2.69, -1.03)

* 58 percent of BARACLUDE-treated patients and 19 percent of adefovir-
treated patients had undetectable viral load (HBV DNA <300 copies/mL,
measured by a common assay -- polymerase chain reaction, or PCR)

Week 24

* BARACLUDE-treated patients achieved a mean change in viral load of -6.97
log(10) copies/mL, and adefovir-treated patients achieved a mean change
of -4.84 log(10) copies/mL (95 percent Confidence Interval -2.51, -1.20)

* 45 percent of BARACLUDE-treated patients and 13 percent of adefovir-
treated patients had undetectable viral load (HBV DNA <300 copies/mL)

Week 12

* BARACLUDE-treated patients achieved a mean change in viral load of -6.23
log(10) copies/mL, and adefovir-treated patients achieved a mean change
of -4.42 log(10) copies/mL (p < 0.0001)

* 12 percent of BARACLUDE(R) (entecavir)-treated patients and 9 percent of
adefovir-treated patients had undetectable viral load (HBV DNA <300
copies/mL)

Adverse events in study ETV-079:

'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Baraclude (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment
2. Point of Care Strep Tests Speed Treatment, Lower Costs
3. Rapid HIV Testing Increases Possibility of Treatment
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
8. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
9. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments: